Lifecore Biomedical targets 12% revenue CAGR and expanded CDMO pipeline by 2027

Stock Information for Lifecore Biomedical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lifecore Biomedical Inc.

Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome
Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.